他汀类药物可提高头颈癌患者的五年生存率：一项对约10万名患者的回顾性病例对照研究。
Statin Medication Improves Five-Year Survival Rates in Patients with Head and Neck Cancer: A Retrospective Case-Control Study of about 100,000 Patients.
作者信息
Wüster Jonas, Heiland Max, Nahles Susanne, Preissner Robert, Preissner Saskia
机构信息
Department of Oral and Maxillofacial Surgery, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Augustenburger Platz 1, 13353 Berlin, Germany.
Institute of Physiology and Science-IT, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Philippstr. 12, 10115 Berlin, Germany.
出版信息
Cancers (Basel). 2023 Jun 7;15(12):3093. doi: 10.3390/cancers15123093.
INTRODUCTION
The overall survival among head and neck cancer patients is still low, even in a time of new therapy regimes. Regarding cancer patients' survival, statin use has already proven to be associated with favorable survival outcomes. Our objective was to investigate the influence of statin medication on the overall survival of head and neck cancer patients.
METHODS
Retrospective clinical data of patients diagnosed with head and neck cancer (International Classification of Diseases codes: C00-C14) were retrieved from a real-world evidence database. The initial cohort was divided into patients with statin medication, who were assigned to building cohort I, and subjects without statin medication, who were assigned to cohort II, both matched by age, gender, and risk factors (nicotine and alcohol abuse/dependence). Subsequently, Kaplan-Meier and risk analyses were performed, and odds and hazard ratios were calculated.
RESULTS
After matching, each cohort contained 48,626 patients (cohort I = females: 15,409; (31.7%), males 33,212 (68.3%); mean age ± standard deviation (SD) at diagnosis 66.3 ± 11.4 years; cohort II = females: 15,432; (31.7%), males 33,187 (68.2%); mean age ± standard deviation (SD) at diagnosis 66.4 ± 11.5 years). Five-year survival was found to be significantly higher for cohort I, with 75.19%, respectively 70.48% for cohort II. These findings were correlated significantly with a risk of death of 15.9% (cohort I) and 17.2% (cohort II); the odds ratio was 0.91 (95% CI: 0.881-0.942) and the hazard ratio 0.80 (0.777-0.827).
CONCLUSIONS
The results indicate that the five-year survival of head and neck cancer patients is significantly improved by statin medication. As this study was conducted retrospectively, our data must be interpreted with caution, especially since other potential influencing factors and the initial tumor stage were not available.
引言
即使在新治疗方案不断涌现的时代，头颈癌患者的总体生存率仍然很低。关于癌症患者的生存率，他汀类药物的使用已被证明与良好的生存结果相关。我们的目的是研究他汀类药物治疗对头颈癌患者总体生存率的影响。
方法
从一个真实世界证据数据库中检索被诊断为头颈癌（国际疾病分类代码：C00-C14）患者的回顾性临床数据。最初的队列被分为服用他汀类药物的患者（归入队列I）和未服用他汀类药物的受试者（归入队列II），两组在年龄、性别和风险因素（尼古丁和酒精滥用/依赖）方面进行匹配。随后进行了Kaplan-Meier分析和风险分析，并计算了优势比和风险比。
结果
匹配后，每个队列包含48,626名患者（队列I = 女性：15,409名（31.7%），男性33,212名（68.3%）；诊断时的平均年龄±标准差（SD）为66.3±11.4岁；队列II = 女性：15,432名（31.7%），男性33,187名（68.2%）；诊断时的平均年龄±标准差（SD）为66.4±11.5岁）。发现队列I的五年生存率显著更高，队列I为75.19%，队列II为70.48%。这些发现与15.9%（队列I）和17.2%（队列II）的死亡风险显著相关；优势比为0.91（95% CI：0.881-0.942），风险比为0.80（0.777-0.827）。
结论
结果表明，他汀类药物治疗可显著提高头颈癌患者的五年生存率。由于本研究是回顾性的，我们的数据必须谨慎解读，特别是因为其他潜在影响因素和初始肿瘤分期不可得。
Zotero 插件